LOGIN  |  REGISTER
C4 Therapeutics
Viking Therapeutics

Chemed Holds Annual Meeting of Stockholders; Board Declares Quarterly Dividend

May 19, 2025 | Last Trade: US$569.79 8.34 1.49

CINCINNATI / May 19, 2025 / Business Wire / Stockholders of Chemed Corporation (NYSE: CHE) today elected a slate of nine directors at the Company’s 2025 annual stockholders’ meeting.

Stockholders ratified the continuation of PricewaterhouseCoopers LLP as the Company’s independent accountants for 2025. Stockholders also approved Chemed’s executive compensation and the Company’s 2025 Stock Incentive Plan.

Dividend Declared

Following the stockholders’ meeting, Chemed’s Board of Directors declared a quarterly cash dividend of 50 cents per share on the Company’s capital stock, payable on June 17, 2025, to stockholders of record as of May 29, 2025. This represents the 216th consecutive quarterly dividend paid to stockholders in Chemed’s 54 years as a public company.

Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation (www.chemed.com) operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care, and Roto-Rooter is the nation’s leading provider of plumbing and drain cleaning services.

Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk and that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.

Chimerix

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page